Cefepime vs. meropenem for moderate-to-severe pneumonia in patients at risk for aspiration: An open-label, randomized study.

J Infect Chemother

Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-kawaharacho, Sakyo, Kyoto 606-8507, Japan.

Published: February 2020

Background: Treatment of aspiration pneumonia is an important problem due to aging of populations worldwide. However, the effectiveness of cefepime in aspiration pneumonia has not yet been evaluated.

Aim: To compare the clinical efficacy and safety of cefepime and meropenem in patients with moderate-to-severe aspiration pneumonia.

Methods: In this open-label, randomized study, either cefepime 1 g or meropenem 0.5 g was administered intravenously every 8 h to patients with moderate-to-severe community-acquired or nursing-home acquired pneumonia at risk for aspiration for an average of 10.5 days. The primary outcome was the clinical response rate at the end of treatment (EOT) in the validated per-protocol (VPP)-population. Secondary outcomes were clinical response during treatment (days 4 and 7) and at the end of study (EOS) in the VPP-population, and survival at day 30 in the modified intention-to-treat (MITT)-population.

Results: There was no difference between the groups in the primary or secondary outcomes or safety. Significant improvement was observed in each group on day 4.

Conclusion: Cefepime is as effective and safe as meropenem in the treatment of moderate-to-severe aspiration pneumonia.

Clinical Trials Identifier: UMIN000001349.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jiac.2019.08.005DOI Listing

Publication Analysis

Top Keywords

cefepime meropenem
8
risk aspiration
8
open-label randomized
8
randomized study
8
aspiration pneumonia
8
patients moderate-to-severe
8
moderate-to-severe aspiration
8
clinical response
8
secondary outcomes
8
aspiration
6

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!